Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824367 | 0.89 | OPRD1 (0.53) | CA12CA1CA2CA9HRH3 | |
| SCHEMBL16639869 | 0.87 | OPRM1 (0.56) | CA12CA1CA2CA9HRH3 | |
| SCHEMBL6247236 | 0.84 | APP (0.59) | APPALDH1A1MAPTTSHR | |
| SCHEMBL20066073 | 0.84 | CYP2D6 (0.49) | HRH3OPRD1ALDH1A1MAPTCHRM4 | |
| SCHEMBL2529921 | 0.83 | CA12 (0.54) | CA12CA1CA2CA9HRH3 | |
| SCHEMBL13183065 | 0.83 | CA12 (0.54) | CA12CA1CA2CA9HRH3 | |
| SCHEMBL20066008 | 0.82 | CYP2D6 (0.48) | HRH3ALDH1A1MAPTCHRM4 | |
| SCHEMBL14031243 | 0.81 | CA12 (0.62) | CA12CA1CA2CA9HRH3 | |
| SCHEMBL21581202 | 0.81 | OPRD1 (0.63) | OPRD1APPOPRM1OPRK1MAPT | |
| SCHEMBL20066079 | 0.81 | CYP2D6 (0.49) | CA12CA1CA2CA9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700587-B2 | Haloperidol analogs | FLORIDA A&M UNIVERSITY (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2007053145-A1 | HALOPERIDOL ANALOGS | FLORIDA A & M UNIVERSITY (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20060052363-A1 | which are incapable of metabolizing to BCPP+ like species, and have affinity for D2 receptor subtype and functions as dopamine receptor antagonist | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052363-A1 | which are incapable of metabolizing to BCPP+ like species, and have affinity for D2 receptor subtype and functions as dopamine receptor antagonist | DBH, TACR1, PRLHR | CA12 1140/4885CA1 939/4885CA2 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.